Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multimodal management of inguinal lymph node metastases from penile squamous cell carcinoma with bilateral lymphadenectomy and TIP chemotherapy
2014-004678-41Phase 2Active
- Sponsor
- Unicancer
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paclitaxel, ifosfamide and cisplatin in penile squamous cell carcinoma (PSCC) (2 arms), sponsored by Unicancer. Primary endpoint: Locoregional nodal recurrence-free survival rate at 24 months. Started Feb 2016; status: active.
02
Drugs
paclitaxelifosfamidecisplatin
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on 2014-004678-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004678-41.